Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

S&P Biotech SPDR (NY: XBI )

94.30 +0.29 (+0.31%)
Official Closing Price Updated: 8:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about S&P Biotech SPDR

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Pivotal Week Coming Up: Big Tech Earnings, Geopolitics, Technicals, Treasury Yield...
The upcoming quarter GDP is expected to hit 3.7% which has brought the FED dialogue to “higher rates for longer” which might lead us to a recession in 2024. So watch the yield on the 10-year TSY now at... 
Via Talk Markets
Topics Economy
Exposures Economy
Thoughts For Thursday: War Worries Rattle The Market
Via Talk Markets
Too Much To Handle For Stocks As Rates Continue To Rise
Stocks finished sharply lower as rates reached new cycle highs on the long end of the curve, and the yield curve steepened. This led to a drop of about 1.3% on the S&P 500, bringing the index down to... 
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Stocks and Bonds Go Their Separate Ways
Stocks were up today by around 1.1% on the S&P 500, but we have gone nowhere now in a week, so the bulls are making no progress. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up
Healthcare has not been a strong sector in 2023. Despite its history of being defensive in turbulent times the sector has underperformed as higher rates curb buyers sentiment. 
Via Talk Markets
Stocks Rally And Rates Drop But Trends Remain In Place
Stocks increased on Wednesday, rising by around 80 bps, as the dollar and rates fell. There is still a lot of data to come this week, with the Job report on Friday now front and center. 
Via Talk Markets
Don’t Miss the Boom: 3 ETFs Set to Explode Higher
The market may be uncertain. But these three ETFs to buy are set to deliver fantastic returns regardless of the broader economic climate. 
Via InvestorPlace
Topics ETFs
Healthcare Playbook Revisited - Growth Plus Value
Despite concerns about rising healthcare costs and ever more expensive technology for treatment encompassing drugs, devices, and data management, still innovative medicine marches on. 
Via Talk Markets
Buy List Alert: 3 Pharma Stocks with Positive Trial Updates
These three pharma stocks could be driven higher amidst future revenue prospects as they report to investors positive clinical developments. 
Via InvestorPlace
EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug
Calliditas, a rare disease company focused on kidney ailments, is optimistic of its lead drug taking off in a big way. 
Via Benzinga
Healthcare Portfolio: A Mixed Market Looking for Value
Many healthcare stocks may be defensive in nature but if you are overweight the basic plays like the XLV or biotech funds like the Fidelity Biotechnology Fund you are trailing the market over the past... 
Via Talk Markets
Life Science Mutual Funds Compared To ETFs And What Is In Your Portfolio?
It is important to track sectors of the market because trends to create volatility. For example the COVID pandemic created a diagnostics and vaccine revenue bubble that dissipated over several months. 
Via Talk Markets
Topics ETFs
Exposures COVID-19
If You Invested $1000 In Vivek Ramaswamy-Founded Roivant When He Declared Presidential Bid, Here's How Much You'd Have Now
Roivant stock has outperformed the broader market and the biotech sector this year, mirroring the rise in the fortunes of its founder Vivek Ramaswamy. 
Via Benzinga
3 Sorry Pharma Stocks to Sell in August Before It’s Too Late
Factors in the marketplace caused these companies to underperform, making them some of the top pharma stocks to sell. 
Via InvestorPlace
5 Meme Stocks to Sell Immediately, According to AI
As we move into September, the MarketMaster AI is flashing warning signals about risky equities. Sell these meme stocks right now. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Playbook Revisited As UNH Beat Could Help Sagging Healthcare Stocks
Last week saw a broadening of the rally as many top sectors were up over 3%. But healthcare was among the laggards up only 0.7%. 
Via Talk Markets
3 Biotech Stocks to Buy for Long-Term Gains
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
“The Secret To Happiness” Stock Market (And Sentiment Results)
There’s an old maxim, “the secret to happiness is low expectations”. This saying could not apply more directly than to what we are seeing coming into the Q2 earnings season. 
Via Talk Markets
Thoughts For Thursday: Back From The Holiday With Caution
Caution is perhaps what was reflected in yesterday's back from the holiday trading. One there is the question of upcoming Fed action and second there is the visit of Secretary Yellen to China. 
Via Talk Markets
Biotech Blues: Stay Balanced Through July Earnings Season
Life Science stocks lack momentum so be prepared for rebalancing and rotation shifts. 
Via Talk Markets
Stocks May Suffer With Rates On The Cusp Of A Surge Higher
It will be a holiday-shortened trading week, with today being a half day, and the market being closed on Tuesday. This will be a hectic week with a lot of data. Starting Monday with the ISM data for... 
Via Talk Markets
The June Job Report Could Push Rates Sharply Higher
This week's June job report could cause rates, the dollar, and even oil to all rise sharply. 
Via Talk Markets
Biotech And Healthcare Stocks Lagging
Healthcare is a laggard with XLV down YTD but UNH is still a core position. 
Via Talk Markets
“The One That Got Away” Stock Market (And Sentiment Results)
It was very lonely being a bull last fall when the S&P 500 was in the 3600s to 3700s. The good news is there’s plenty of runway ahead. The bad news is, it’s going to be a bit more tricky. 
Via Talk Markets
Market Mixes It Up With A Broad Rally
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. 
Via Talk Markets
“Skip Or Flip” Stock Market (And Sentiment Results)
We are at the cusp of a sea change, and the knock-on effects will be material. We expect to see two meaningful changes in the coming months as a result of the Fed being done. 
Via Talk Markets
A Good Week For The Market But A Pause In The Biotech Rally
Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness. 
Via Talk Markets
The Dierks Bentley “Feels Like Gold” Stock Market (And Sentiment Results)
Markets top when everyone is overweight stocks on margin. We are nowhere close to that point 
Via Talk Markets
Why These 3 Nasdaq Stocks Buckled Today
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today. 
Via The Motley Fool
Time To Play Small Cap Life Science Stocks
The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.